Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Cagrilintide clinical trial results The phase 2 dose-finding trial enrolled participants with overweight or obesity and tested cagrilintide doses ranging from 0.3 mg to 4.5 mg administered subcutaneously once weekly
Is it once daily, or 5-days-on / 2-off
It works by reducing hunger and promoting feelings of fullness, aiding in weight loss
When injecting, the medication should be slowly pushed to avoid local pain or drug leakage caused by too fast injection speed
The molecular target that AOD-9604 actually binds is still unidentified, which the FDA explicitly noted in its December 2024 evaluation
International Journal of General Medicine, 2011
